Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions ā€” written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Thrombophilia primary prevention

Introduction

Overview

Overview

Thromboprophylaxis with anticoagulation may be recommended for primary prevention of acute thrombosis in high risk acquired and inherited thrombophilias.[1][2][3][4][5][6]

Primary Prevention

Primary Prevention

  • Thrombosis Prevention:
    • There is no evidence to support the long-term pharmacological primary thromboprophylaxis of asymptomatic family members found to have a thrombophilic genotype.
    • Additionally, patients who experience a thrombotic event towards the end of their period of anticoagulant treatment course should be counseled about the signs and symptoms of thromboembolism and made aware about the requirement to seek an early medical attention on suspicion of a recurrence.
    • Moreover, they should be advised to mention their history of VTE to their physicians so that appropriate decisions about short-term thromboprophylaxis at times of increased thrombotic risk can be made.
    • Hence, all patients with a past history of VTE with or without evidence of a thrombophilic defect merit consideration for short-term thromboprophylaxis to cover periods of increased thrombotic risk such as surgery, trauma, plaster casts or immobilization.
Table 1: Enlist the indications for thromboprophylaxis with anticoagulation[1][2][3][4][5][6]
Indications for thromboprophylaxis
References

References

  1. ā†‘ 1.0 1.1 DeLoughery TG. Hemostasis and Thrombosis: Springer International Publishing; 2014.
  2. ā†‘ 2.0 2.1 Cohoon KP, Heit JA (2014). “Inherited and secondary thrombophilia”. Circulation. 129 (2): 254ā€“7. doi:10.1161/CIRCULATIONAHA.113.001943. PMCĀ 3979345. PMIDĀ 24421360.
  3. ā†‘ 3.0 3.1 Seligsohn U, Lubetsky A (2001). “Genetic susceptibility to venous thrombosis”. N Engl J Med. 344 (16): 1222ā€“31. doi:10.1056/NEJM200104193441607. PMIDĀ 11309638.
  4. ā†‘ 4.0 4.1 Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S; et al. (2012). “Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines”. Chest. 141 (2 Suppl): e278Sā€“325S. doi:10.1378/chest.11-2404. PMCĀ 3278063. PMIDĀ 22315265.
  5. ā†‘ 5.0 5.1 Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A; et al. (2002). “Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer”. N Engl J Med. 346 (13): 975ā€“80. doi:10.1056/NEJMoa012385. PMIDĀ 11919306.
  6. ā†‘ 6.0 6.1 Agnelli G (2004). “Prevention of venous thromboembolism in surgical patients”. Circulation. 110 (24 Suppl 1): IV4ā€“12. doi:10.1161/01.CIR.0000150639.98514.6c. PMIDĀ 15598646.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Asiri Ediriwickrema, M.D., M.H.S. [2] Jaspinder Kaur, MBBS[3]